Enhancing Mood, Cognition, and Quality of Life in Pediatric Multiple Sclerosis

Paediatr Drugs. 2021 Jul;23(4):317-329. doi: 10.1007/s40272-021-00451-5. Epub 2021 May 17.

Abstract

Pediatric-onset multiple sclerosis (POMS), representing approximately 5% of all MS cases, affects the central nervous system during its ongoing development. POMS is most commonly diagnosed during adolescence but can occur in younger children as well. For pediatric patients with MS, it is critical to manage the full impact of the disease and monitor for any effects on school and social functioning. Disease management includes not only disease-modifying therapies but also strategies to optimize wellbeing. We review the interventions with the highest evidence of ability to improve the disease course and quality of life in POMS. High levels of vitamin D and a diet low in saturated fat are associated with lower relapse rates. Exercise ameliorates fatigue and sleep. Behavioral strategies for sleep hygiene and mood regulation can also improve fatigue and perceived health. POMS management should be addressed holistically, including assessing overall symptom burden as well as the psychological and functional impact of the disease.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Affect / physiology*
  • Antioxidants / administration & dosage
  • Child
  • Cognition / physiology*
  • Disease Management
  • Exercise / physiology
  • Exercise / psychology
  • Fatigue / etiology
  • Fatigue / psychology
  • Fatigue / therapy
  • Humans
  • Longitudinal Studies
  • Medical Marijuana / administration & dosage
  • Multiple Sclerosis / complications
  • Multiple Sclerosis / psychology*
  • Multiple Sclerosis / therapy*
  • Quality of Life / psychology*
  • Vitamin D / administration & dosage

Substances

  • Antioxidants
  • Medical Marijuana
  • Vitamin D